Latest Insights

Have you heard the news? The DEA is considering moving cannabis to a Schedule III substance. This change in federal law would fundamentally shift the cannabis industry, immediately getting rid...

Success in the California market often starts with a single shop. You learn the ropes, find your flow, and build a local brand. But as you scale to three or...

Maximize the 280E cannabis tax dividend by restructuring debt and funding FDA compliance to ensure long-term success in 2026.

Prepare for the shift to Schedule III drugs as cannabis moves to FDA oversight. Learn about cGMP compliance, insurance risks, and avoiding federal enforcement actions.

Master the true cost of a budtender salary by factoring in Workers' Comp, EMOD scores, and avoiding expensive audit traps.

Analyze the STIIIZY lawsuits to discover how federal rescheduling transforms cannabis risk from a legal exception into a high-stakes, regulated operating environment.